Cannabidiol (CBD) as a novel treatment in the early phases of psychosis.

Chesney, Edward; Oliver, Dominic; McGuire, Philip

Chesney, Edward; Oliver, Dominic; McGuire, Philip.

Afiliação

Chesney E; Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. edward.chesney@kcl.ac.uk.
Oliver D; South London and Maudsley NHS Foundation Trust, London, UK. edward.chesney@kcl.ac.uk.
McGuire P; Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.

Psychopharmacology (Berl) ; 239(5): 1179-1190, 2022 May.

Article em En | MEDLINE | ID: mdl-34255100

Assuntos

Antipsicóticos; Canabidiol; Canabinoides; Cannabis; Transtornos Psicóticos; Antipsicóticos/efeitos adversos; Canabidiol/efeitos adversos; Canabinoides/uso terapêutico; Humanos; Transtornos Psicóticos/tratamento farmacológico

Palavras-chave

Antipsychotics; CBD; Cannabidiol; Cannabinoids; Clinical high risk; First-episode psychosis; Psychosis; Schizophrenia; Treatment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtornos Psicóticos / Antipsicóticos / Canabidiol / Canabinoides / Cannabis Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google